Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 60.0 | 63 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 40.5 | 54 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 49.5 | 36 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 53.0 | 50 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 56.5 | 62 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 897.0 | 50 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | IP-10 | 1414.0 | 53 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 1282.5 | 54 | |
N2645 | TNF-a | 100 | ng/mL | 4 | IP-10 | 2372.0 | 57 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 588.0 | 60 | |
RA2708 | TNF-a | 100 | ng/mL | 4 | IP-10 | 1756.0 | 49 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 4 | IP-10 | 20.0 | 50 | ||||
RA2159 | IKK16 | 2.0 | uM | 4 | IP-10 | 16.0 | 54 | ||||
N2645 | 5z-7-oxozeaenol | 0.6 | uM | 4 | IP-10 | 18.0 | 63 | ||||
N2645 | IKK16 | 2.0 | uM | 4 | IP-10 | 18.0 | 44 | ||||
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | 4 | IP-10 | 17.0 | 55 | ||||
RA2708 | IKK16 | 2.0 | uM | 4 | IP-10 | 22.0 | 56 | ||||
RA2159 | Tofacitinib | 0.3 | uM | 4 | IP-10 | 15.0 | 68 | ||||
RA2159 | 4 | IP-10 | 15.0 | 58 | |||||||
N2645 | Tofacitinib | 0.3 | uM | 4 | IP-10 | 14.5 | 40 | ||||
N2645 | 4 | IP-10 | 16.0 | 60 | |||||||
RA2708 | Tofacitinib | 0.3 | uM | 4 | IP-10 | 17.5 | 42 | ||||
RA2708 | 4 | IP-10 | 15.0 | 47 | |||||||
RA2159 | 4 | IP-10 | 17.0 | 49 | |||||||
N2645 | 4 | IP-10 | 13.0 | 53 |